Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer

Cancer Treatment Reviews

Volumn 40, Issue 6, 2014, Pages 750-759

  Brechbiel, Jillian ^a   Miller Moslin, Karen ^a   Adjei, Alex A ^b  

^a Articulate Science   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cell signaling; Combination chemotherapy; Hedgehog; Novel antitumor agents; Smoothened; Targeted therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BEVACIZUMAB; BMS 833923; CISPLATIN; CYCLOPAMINE; DACTOLISIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; GLASDEGIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MRK 003; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NILOTINIB; NOTCH RECEPTOR; PONATINIB; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; RUXOLITINIB; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VISMODEGIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; EMBRYO DEVELOPMENT; HEMATOPOIESIS; HUMAN; NONHUMAN; REVIEW; SOLID TUMOR;

CELL SIGNALING; COMBINATION CHEMOTHERAPY; HEDGEHOG; NOVEL ANTITUMOR AGENTS; SMOOTHENED; TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FUSION PROTEINS, BCR-ABL; HEDGEHOG PROTEINS; HUMANS; JANUS KINASE 2; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84899898581     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.02.003     Document Type: Review

References (116)

1. McMahon A.P., Ingham P.W., Tabin C.J. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003, 53:1-114.
2. Lin T.L., Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. Onco Targets Ther 2012, 5:47-58.
3. Sahebjam S., Siu L.L., Razak A.A. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 2012, 17:1090-1099.
4. Varjosalo M., Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008, 22:2454-2472.
5. D'Angelo R.C., Wicha M.S. Stem cells in normal development and cancer. Prog Mol Biol Transl Sci 2010, 95:113-158.
6. Ryan K.E., Chiang C. Hedgehog secretion and signal transduction in vertebrates. J Biol Chem 2012, 287:17905-17913.
7. Scales S.J., de Sauvage F.J. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009, 30:303-312.
8. Caro I., Low J.A. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010, 16:3335-3339.
9. Romer J., Curran T. Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 2005, 65:4975-4978.
10. Belyea B., Kephart J.G., Blum J., Kirsch D.G., Linardic C.M. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma 2012, 2012:406239.
11. Long B., Zhu H., Zhu C., Liu T., Meng W. Activation of the hedgehog pathway in chronic myelogeneous leukemia patients. J Exp Clin Cancer Res 2011, 30:8.
12. Theunissen J.W., de Sauvage F.J. Paracrine hedgehog signaling in cancer. Cancer Res 2009, 69:6007-6010.
13. Becher O.J., Hambardzumyan D., Fomchenko E.I., et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 2008, 68:2241-2249.
14. Dierks C., Grbic J., Zirlik K., et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007, 13:944-951.
15. Hegde G.V., Peterson K.J., Emanuel K., et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol Cancer Res 2008, 6:1928-1936.
16. Wilkinson S.E., Furic L., Buchanan G., et al. Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate 2013, 73:1810-1823.
17. O'Toole S.A., Machalek D.A., Shearer R.F., et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011, 71:4002-4014.
18. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
19. Mills L.D., Zhang Y., Marler R.J., et al. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J Biol Chem 2013, 288:11786-11794.
20. Tian H., Callahan C.A., DuPree K.J., et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA 2009, 106:4254-4259.
21. Amakye D., Jagani Z., Dorsch M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat Med 2013, 19:1410-1422.
22. Heller E., Hurchla M.A., Xiang J., et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res 2012, 72:897-907.
23. Merchant A.A., Matsui W. Targeting hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010, 16:3130-3140.
24. Liu S., Dontu G., Mantle I.D., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006, 66:6063-6071.
25. Clement V., Sanchez P., de Tribolet N., Radovanovic I., Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007, 17:165-172.
26. Bar E.E., Chaudhry A., Lin A., et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25:2524-2533.
27. Varnat F., Duquet A., Malerba M., et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009, 1:338-351.
28. Feldmann G., Fendrich V., McGovern K., et al. An orally bioavailable small-molecule inhibitor of hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008, 7:2725-2735.
29. Jeng K.S., Sheen I.S., Jeng W.J., et al. Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1-6 cells. Onco Targets Ther 2013, 6:1047-1055.
30. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
31. Jagani Z., Dorsch M., Warmuth M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010, 9:3449-3456.
32. Peacock C.D., Wang Q., Gesell G.S., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007, 104:4048-4053.
33. Blotta S., Jakubikova J., Calimeri T., et al. Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012, 120:5002-5013.
34. Fu J., Rodova M., Nanta R., et al. NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. Neuro Oncol 2013, 15:691-706.
35. Nanta R., Kumar D., Meeker D., et al. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis 2013, 2:e42.
36. Farooqi A.A., Mukhtar S., Riaz A.M., et al. Wnt and SHH in prostate cancer: trouble mongers occupy the TRAIL towards apoptosis. Cell Prolif 2011, 44:508-515.
37. Kim J.H., Shin H.S., Lee S.H., et al. Contrasting activity of hedgehog and Wnt pathways according to gastric cancer cell differentiation: relevance of crosstalk mechanisms. Cancer Sci 2010, 101:328-335.
38. Javelaud D., Pierrat M.J., Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS Lett 2012, 586:2016-2025.
39. Li X., Ma Q., Xu Q., et al. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of hedgehog pathway. Cancer Lett 2012, 322:169-176.
40. Chen M., Feuerstein M.A., Levina E., et al. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer 2010, 9:89.
41. Dentice M., Luongo C., Huang S., et al. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci USA 2007, 104:14466-14471.
42. Lauth M. RAS and hedgehog-partners in crime. Front Biosci 2011, 16:2259-2270.
43. Fremin C., Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010, 3:8.
44. Pasca di Magliano M., Sekine S., Ermilov A., Ferris J., Dlugosz A.A., Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 2006, 20:3161-3173.
45. Morton J.P., Mongeau M.E., Klimstra D.S., et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 2007, 104:5103-5108.
46. Lauth M., Bergstrom A., Shimokawa T., et al. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol 2010, 17:718-725.
47. Ji Z., Mei F.C., Xie J., Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007, 282:14048-14055.
48. Nolan-Stevaux O., Lau J., Truitt M.L., et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009, 23:24-36.
49. Lauth M., Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 2007, 6:2458-2463.
50. Rajurkar M., De Jesus-Monge W.E., Driscoll D.R., et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci USA 2012, 109:E1038-E1047.
51. Mazumdar T., DeVecchio J., Agyeman A., Shi T., Houghton J.A. The GLI genes as the molecular switch in disrupting hedgehog signaling in colon cancer. Oncotarget 2011, 2:638-645.
52. Stecca B., Mas C., Clement V., et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007, 104:5895-5900.
53. Seto M., Ohta M., Asaoka Y., et al. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog 2009, 48:703-712.
54. Dimou A., Syrigos K., Saif M.W. Rationale for inhibition of the hedgehog pathway paracrine loop in pancreatic adenocarcinoma. JOP 2011, 12:1-5.
55. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
56. Mangelberger D., Kern D., Loipetzberger A., Eberl M., Aberger F. Cooperative hedgehog-EGFR signaling. Front Biosci 2012, 17:90-99.
57. Krauss S., Foerster J., Schneider R., Schweiger S. Protein phosphatase 2A and rapamycin regulate the nuclear localization and activity of the transcription factor GLI3. Cancer Res 2008, 68:4658-4665.
58. Riobo N.A., Lu K., Ai X., Haines G.M., Emerson C.P. Phosphoinositide 3-kinase and Akt are essential for sonic hedgehog signaling. Proc Natl Acad Sci USA 2006, 103:4505-4510.
59. Metcalfe C., Alicke B., Crow A., et al. PTEN loss mitigates the response of medulloblastoma to hedgehog pathway inhibition. Cancer Res 2013, 73:7034-7042.
60. Wei L., Xu Z. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer 2011, 129:275-284.
61. Wang Y., Ding Q., Yen C.J., et al. The crosstalk of mTOR/S6K1 and hedgehog pathways. Cancer Cell 2012, 21:374-387.
62. Das S., Samant R.S., Shevde L.A. Nonclassical activation of hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting hedgehog inhibition. J Biol Chem 2013, 288:11824-11833.
63. Yoo Y.A., Kang M.H., Lee H.J., et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res 2011, 71:7061-7070.
64. Kaylani S.Z., Xu J., Srivastava R.K., Kopelovich L., Pressey J.G., Athar M. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model. Biochem Biophys Res Commun 2013, 435:557-561.
65. Hao K., Tian X.D., Qin C.F., Xie X.H., Yang Y.M. Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. Oncol Rep 2013, 29:1124-1132.
66. Wu W.K., Wang X.J., Cheng A.S., et al. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol 2013, 86:251-277.
67. Palma V., Lim D.A., Dahmane N., et al. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development 2005, 132:335-344.
68. Bigelow R.L., Jen E.Y., Delehedde M., Chari N.S., McDonnell T.J. Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes. J Invest Dermatol 2005, 124:457-465.
69. Schnidar H., Eberl M., Klingler S., et al. Epidermal growth factor receptor signaling synergizes with hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009, 69:1284-1292.
70. Eberl M., Klingler S., Mangelberger D., et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012, 4:218-233.
71. Gotschel F., Berg D., Gruber W., et al. Synergism between hedgehog-GLI and EGFR signaling in hedgehog-responsive human medulloblastoma cells induces downregulation of canonical hedgehog-target genes and stabilized expression of GLI1. PLoS One 2013, 8:e65403.
72. Keysar S.B., Le P.N., Anderson R.T., et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res 2013, 73:3381-3392.
73. Guo S., Liu M., Gonzalez-Perez R.R. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011, 1815:197-213.
74. Ingram W.J., McCue K.I., Tran T.H., Hallahan A.R., Wainwright B.J. Sonic hedgehog regulates Hes1 through a novel mechanism that is independent of canonical notch pathway signalling. Oncogene 2008, 27:1489-1500.
75. Katoh M. Networking of WNT, FGF, notch, BMP, and hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 2007, 3:30-38.
76. Schreck K.C., Taylor P., Marchionni L., et al. The notch target Hes1 directly modulates Gli1 expression and hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 2010, 16:6060-6070.
77. Androutsellis-Theotokis A., Leker R.R., Soldner F., et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006, 442:823-826.
78. Steg A.D., Katre A.A., Goodman B., et al. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res 2011, 17:5674-5685.
79. Domingo-Domenech J., Vidal S.J., Rodriguez-Bravo V., et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22:373-388.
80. Ok C.Y., Singh R.R., Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol 2012, 180:2-11.
81. Bhagwat N, Keller MD, Rampal R, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. American Society of Hematology, Meeting Abstracts 2013: abstr 666.
82. Mahindroo N., Punchihewa C., Fujii N. Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J Med Chem 2009, 52:3829-3845.
83. Lorusso P.M., Rudin C.M., Reddy J.C., et al. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin Cancer Res 2011, 17:2502-2511.
84. Sekulic A., Migden M.R., Oro A.E., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366:2171-2179.
85. Chitkara D., Singh S., Kumar V., et al. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Mol Pharm 2012, 9:2350-2357.
86. Hu W.G., Liu T., Xiong J.X., Wang C.Y. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol Sin 2007, 28:1224-1230.
87. Shaw G., Prowse D.M. Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int 2008, 8:3.
88. Mimeault M., Johansson S.L., Vankatraman G., et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007, 6:967-978.
89. Maitah M., Ali S., LoRusso P., Sarkar F.H., Gadgeel S.M. The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. J Clin Oncol 2011, 29. abstr 10537.
90. Mandley E., White K., Faia K., et al. The Hh inhibitor IPI-926 inhibits relapse of a non-small cell lung cancer xenograft model following treatment with an EGF-R targeted tyrosine kinase inhibitor 2010, American Association for Cancer Research Congress, abstr 5045.
91. Ahmad A., Maitah M.Y., Ginnebaugh K.R., et al. Inhibition of hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 2013, 6:77.
92. Eimer S., Dugay F., Airiau K., et al. Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro Oncol 2012, 14:1441-1451.
93. Gioeli D., Wunderlich W., Sebolt-Leopold J., et al. Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 2011, 10:1581-1590.
94. Jinawath A., Akiyama Y., Sripa B., Yuasa Y. Dual blockade of the hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol 2007, 133:271-278.
95. Keysar S., Anderson R., Takimoto S., et al. Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC). J Clin Oncol 2010, ASCO Annual Meeting Proceedings 2010;28:suppl. 15s: abstr 5558.
96. Buonamici S., Williams J., Morrissey M., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010, 2. 51ra70.
97. Gruber Filbin M., Dabral S.K., Pazyra-Murphy M.F., et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med 2013, 19:1518-1523.
98. Filbin G., et al. Activation of sonic hedgehog and PI3K promotes GBM growth. Cancer Discov 2013, 3. OF12, 8290.CD-RW2013-221. Epub 2013 Oct 10.
99. Mueller M.T., Hermann P.C., Witthauer J., et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
100. Okuhashi Y., Itoh M., Nara N., Tohda S. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res 2011, 31:893-896.
101. Ulasov I.V., Nandi S., Dey M., Sonabend A.M., Lesniak M.S. Inhibition of sonic hedgehog and notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 2011, 17:103-112.
102. Ristorcelli E., Lombardo D. Targeting notch signaling in pancreatic cancer. Expert Opin Ther Targets 2010, 14:541-552.
103. Chomel J.C., Turhan A.G. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011, 2:713-727.
104. Al Baghdadi T., Abonour R., Boswell H.S. Novel combination treatments targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma Leuk 2012, 12:94-105.
105. Liao H.F., Su Y.C., Zheng Z.Y., et al. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells. Biomed Pharmacother 2012, 66:378-383.
106. Okabe S., Tauchi T., Tanaka Y., Katagiri S., Ohyashiki K. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Stem Cells Dev 2012, 21:2939-2948.
107. Schairer A, Shih A, Geron I, et al. Human blast crisis leukemia stem cell inhibition with a novel smoothened antagonist. Blood ASH Annual, Meeting Abstracts 2010;116: abstr 1223.
108. David A., Zhang B., Ho Y., et al. Combination of the hedgehog pathway inhibitor LDE225 and nilotinib targets the leukemic stem cell population in chronic myeloid leukaemia. Haematologica 2011, 96(suppl. 2). abstr 521.
109. Katagiri S., Tauchi T., Okabe S., et al. Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res 2013, 19:1422-1432.
110. Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T, Ohyashiki K. Combined effects of the hedgehog pathway inhibitor LDE225 and nilotinib in a random mutagenesis screen. Blood ASH Annual, Meeting Abstracts 2010;116: abstr 595.
111. Mesa R.A. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma 2013, 54:242-251.
112. ClinicalTrials.gov.
113. Palmer C., Erlichman M., Fernandez-Zapico Y., et al. Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. J Clin Oncol 2011, 29. abstr 3092.
114. Erlichman C., Fernandez-Zapico M., Borad M., et al. Phase I trial of the combined targeting of the hedgehog (GDC-0449) and EGFR pathways (erlotinib) in pancreatic cancer. Mol Cancer Ther 2010, abstr 1807.
115. Berlin J., Bendell J.C., Hart L.L., et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 2013, 19:258-267.
116. Gounder M.M., Dickson M.A., Wu N., et al. A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma. J Clin Oncol 2012, ASCO Annual Meeting Proceedings 2012;30:suppl: abstr 10004.